|
|||||
|
|
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease |
|
| Authors: | B. Christensen D. Micic P. R. Gibson A. Yarur E. Bellaguarda P. Corsello J. N. Gaetano J. Kinnucan V. L. Rao S. Reddy S. Singh J. Pekow D. T. Rubin |
| Affiliation: | 1. Alfred Hospital and Monash University, Melbourne, Australia;2. Royal Melbourne Hospital, Melbourne, Australia;3. University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA;4. Northwestern University Feinberg School of Medicine, Chicago, IL, USA;5. Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA;6. University of Michigan Health System, Ann Arbor, MI, USA |
| Abstract: | |
| Keywords: | |